Search company, investor...

Founded Year

2002

Stage

Take Private | Alive

Total Raised

$121M

Valuation

$0000 

Revenue

$0000 

About Intercept Pharmaceuticals

Intercept Pharmaceuticals engages in the development and commercialization of novel therapeutics in the healthcare sector. Its offerings include the development and delivery of medicines for conditions such as primary biliary cholangitis and severe alcohol-associated hepatitis. The company primarily serves the healthcare industry, with a particular emphasis on liver health. It was founded in 2002 and is based in Morristown, New Jersey.

Headquarters Location

305 Madison Avenue

Morristown, New Jersey, 07960,

United States

844-782-4278

Loading...

Loading...

Intercept Pharmaceuticals Patents

Intercept Pharmaceuticals has filed 76 patents.

The 3 most popular patent topics include:

  • transcription factors
  • hepatology
  • intracellular receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/14/2022

11/7/2023

G protein coupled receptors, Rare diseases, Clusters of differentiation, Immune system, Autoimmune diseases

Grant

Application Date

4/14/2022

Grant Date

11/7/2023

Title

Related Topics

G protein coupled receptors, Rare diseases, Clusters of differentiation, Immune system, Autoimmune diseases

Status

Grant

Latest Intercept Pharmaceuticals News

Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer

Jan 22, 2024

| Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer News provided by Share this article Share toX The non-alcoholic fatty liver disease market size is supposed to grow during the forecast period owing to the expected launch of novel emerging therapies, which shall fuel the growth of the non-alcoholic fatty liver disease market during the forecast period, i.e., 2023–2032. LAS VEGAS , Jan. 22, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Fatty Liver Disease Market Insights  report includes a comprehensive understanding of current treatment practices, NAFLD emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Non-Alcoholic Fatty Liver Disease Market Report According to DelveInsight's analysis, the market size for NAFLD across the 7MM is expected to grow with a significant CAGR by 2032. DelveInsight's analysis reveals that in the US most cases of NAFLD are found to be in between 40-60 years old adults compared to the 16-39 age group in 2022. Leading non-alcoholic fatty liver disease companies such as MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others are developing novel NAFLD drugs that can be available in the NAFLD market in the coming years. The promising non-alcoholic fatty liver disease therapies in the pipeline include MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others. Non-Alcoholic Fatty Liver Disease Overview Non-alcoholic fatty liver disease (NAFLD) is a comprehensive term encompassing a range of liver conditions involving the accumulation of fat, spanning from basic steatosis to more advanced stages characterized by associated hepatitis, fibrosis, cirrhosis, and, in some instances, hepatocellular carcinoma. While many individuals may harbor liver fat without evident symptoms or complications, in certain cases, the deposited fat triggers inflammation, leading to cellular damage and impaired liver functionality. The precise cause of NAFLD remains unknown, but it is often associated with factors such as overweight or obesity, type 2 diabetes or pre-diabetes, abnormal lipid levels in the blood, among others. For most individuals, there are no discernible symptoms, but in some cases, inflammation from the fat can damage liver cells, hindering the organ's proper function. The likelihood of developing NAFLD, whether in the form of simple fatty liver or non-alcoholic steatohepatitis (NASH), increases with factors like excess weight, type 2 diabetes or pre-diabetes, and abnormal lipid levels in the blood. A definitive diagnosis of NASH can only be established through a liver biopsy, which not only confirms the condition but also provides insights into the severity of the disease. Importantly, liver biopsy is more adept at detecting fibrosis at earlier stages than elastography. Non-Alcoholic Fatty Liver Disease Epidemiology Segmentation The NAFLD epidemiology section provides insights into the historical and current NAFLD patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The NAFLD market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total NAFLD Prevalent Cases Non-Alcoholic Fatty Liver Disease Treatment Market Currently, there are no approved treatments for NAFLD by regulatory agencies such as the FDA, EMA, or PMDA. However, researchers are exploring potential medications to address this condition. The primary approach for treating NAFLD involves lifestyle changes, including adjustments to diet and exercise. In addition to these modifications, alternative options for treating non-alcoholic steatohepatitis (NASH) have involved the off-label use of vitamin E and anti-diabetes medications like pioglitazone and liraglutide. The NAFLD practice guidance from the American Association for the Study of Liver Diseases (AASLD) suggests considering the off-label use of vitamin E for non-cirrhotic, non-diabetic individuals with biopsy-confirmed NASH and pioglitazone for managing diabetic patients with biopsy-confirmed NASH. Vitamin E, recognized for its antioxidant properties, is regarded as an initial pharmacological approach in addressing NASH, particularly when dietary and lifestyle adjustments prove inadequate. Agents with antifibrotic properties can halt the advancement from liver fibrosis and NAFLD to fibrotic NASH. While the impact of pioglitazone (an anti-diabetic agent) on NASH histology in individuals with T2D has been thoroughly established, certain apprehensions linger, including issues like weight gain, fluid retention, cancer risk, and susceptibility to bone fractures. Additionally, other focuses for treating NAFLD and NASH include G protein-coupled receptors (GPCRs), estrogen-related receptor alpha (ERRα), bone morphogenetic proteins (BMPs), and KLFs. Bariatric surgery, also known as weight loss surgery, is considered the most efficient method to address obesity and diabetes. This procedure works by decreasing food absorption and adjusting gut hormone secretion and metabolic issues. Non-Alcoholic Fatty Liver Disease Pipeline Therapies and Key Companies MN-001: MediciNova Non-Alcoholic Fatty Liver Disease Market Dynamics The dynamics of the non-alcoholic fatty liver disease market are expected to change in the coming years. The increasing research activities and numerous ongoing clinical trials for NASH indicate a growing number of drug developments that are poised to strengthen the NAFLD market, presenting lucrative opportunities for NAFLD market growth in the 7MM due to the substantial presence of a large pool of patients suffering from NASH. Furthermore, as many potential therapies are being investigated for the treatment of NAFLD, and it is safe to predict that the treatment space will significantly impact the NAFLD market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the NAFLD market in the 7MM. However several factors may impede the growth of the non-alcoholic fatty liver disease market. The diagnosis of NASH involves an invasive procedure, and the launch of generics will pose a threat to new emerging therapies due to their cost-effectiveness. Moreover, NAFLD treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the NAFLD market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the NAFLD market growth. Non-Alcoholic Fatty Liver Disease Market Report Metrics Details Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Non-Alcoholic Fatty Liver Disease Companies MediciNova, Eli Lilly and Company, AstraZeneca, Inventiva Pharma, Oasis Pharmaceuticals, LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics Inc., Akero Therapeutics, Inc, Pfizer, Boehringer Ingelheim, Neuraly, Inc., Merck Sharp & Dohme LLC, Rivus Pharmaceuticals, Inc., Hepion Pharmaceuticals, Inc., and others Key Pipeline Non-Alcoholic Fatty Liver Disease Therapies MN-001, LY3885125, AZD7503, Lanifibranor, OA-235i, Resmetirom, BMN 255, GSK4532990, Saroglitazar Magnesium 4 mg Tablet, Efruxifermin, PF-06865571, BI 3006337, DD01, Efinopegdutide, HU6, Rencofilstat, and others Scope of the Non-Alcoholic Fatty Liver Disease Market Report Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and emerging therapies Non-Alcoholic Fatty Liver Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Non-Alcoholic Fatty Liver Disease Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Non-Alcoholic Fatty Liver Disease Market Access and Reimbursement Table of Contents Non-Alcoholic Fatty Liver Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NAFLD companies, including BeiGene, Inventiva Pharma, Cirius Therapeutics, Madrigal Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Enanta Pharmaceuticals, Cascade Pharmaceuticals, among others. Nonalcoholic Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, among others. Nonalcoholic Steatohepatitis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us

Intercept Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Intercept Pharmaceuticals founded?

    Intercept Pharmaceuticals was founded in 2002.

  • Where is Intercept Pharmaceuticals's headquarters?

    Intercept Pharmaceuticals's headquarters is located at 305 Madison Avenue, Morristown.

  • What is Intercept Pharmaceuticals's latest funding round?

    Intercept Pharmaceuticals's latest funding round is Take Private.

  • How much did Intercept Pharmaceuticals raise?

    Intercept Pharmaceuticals raised a total of $121M.

  • Who are the investors of Intercept Pharmaceuticals?

    Investors of Intercept Pharmaceuticals include Interstellar Acquisition, Genextra, OrbiMed Advisors, BAM Elevate and JAFCO Life Science Investment.

  • Who are Intercept Pharmaceuticals's competitors?

    Competitors of Intercept Pharmaceuticals include Immunomic Therapeutics, Constellation Pharmaceuticals, CVRx, Bellicum Pharmaceuticals, Regulus Therapeutics and 7 more.

Loading...

Compare Intercept Pharmaceuticals to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.

A
Aderis Pharmaceuticals

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

K
KeyNeurotek Pharmaceuticals

KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.

A
Asterion

Asterion is a provider of web hosting services, domain registration, and cloud computing solutions within the digital services industry. The company offers tools for building websites, hosting ecommerce platforms, and professional email services, as well as a range of server options including virtual private servers and dedicated hosting. Asterion caters to a wide array of customers, from individuals to businesses, seeking digital presence and cloud infrastructure. It was founded in 2001 and is based in Marlborough, Massachusetts.

A
Ascent Therapeutics

Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.

T
Traversa Therapeutics

Traversa Therapeutics is a company that operates in the healthcare sector, with a focus on developing therapeutic treatments. The company's main offerings include the development and provision of various therapeutic treatments designed to address different health conditions. It was founded in 2006 and is based in La Jolla, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.